Enhancing phage therapy through synthetic biology and genome engineering
Name
1-s2.0-S0958166920301646-main.pdf
Description
Published version
Size
1.94 MB
Format
Adobe PDF
Checksum (MD5)
5e29bed871710733eed7cbe12dbaa314
Author(s)
Lenneman, Bryan R
Fernbach, Jonas
Loessner, Martin J
Lu, Timothy K
Kilcher, Samuel
Date Issued
December 2020
Journal
Current Opinion in Biotechnology
Publisher
Elsevier BV
Citation
Lenneman, Bryan R. et al. "Enhancing phage therapy through synthetic biology and genome engineering." Current Opinion in Biotechnology 68 (April 2021): 151-159 © 2020 The Author(s)
Version
Final published version
Abstract
The antimicrobial and therapeutic efficacy of bacteriophages is currently limited, mostly due to rapid emergence of phage-resistance and the inability of most phage isolates to bind and infect a broad range of clinical strains. Here, we discuss how phage therapy can be improved through recent advances in genetic engineering. First, we outline how receptor-binding proteins and their relevant structural domains are engineered to redirect phage specificity and to avoid resistance. Next, we summarize how phages are reprogrammed as prokaryotic gene therapy vectors that deliver antimicrobial ‘payload’ proteins, such as sequence-specific nucleases, to target defined cells within complex microbiomes. Finally, we delineate big data- and novel artificial intelligence-driven approaches that may guide the design of improved synthetic phage in the future.
MIT Department
Massachusetts Institute of Technology. Research Laboratory of Electronics
Massachusetts Institute of Technology. Synthetic Biology Center
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.copbio.2020.11.003
